Repligen (NASDAQ:RGEN) Upgraded at StockNews.com

Repligen (NASDAQ:RGEN) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Friday.

Other research analysts have also recently issued research reports about the stock. Royal Bank of Canada restated an “outperform” rating and set a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Canaccord Genuity Group started coverage on Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock. Canaccord Genuity Group started coverage on Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. Finally, Wolfe Research initiated coverage on Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Repligen has a consensus rating of “Moderate Buy” and a consensus target price of $185.20.

Repligen Stock Performance

NASDAQ:RGEN traded up $6.85 during mid-day trading on Friday, hitting $149.90. 504,733 shares of the company traded hands, compared to its average volume of 401,016. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The stock’s fifty day moving average price is $144.96 and its 200-day moving average price is $142.20. The firm has a market cap of $8.40 billion, a price-to-earnings ratio of -405.12, a price-to-earnings-growth ratio of 4.64 and a beta of 0.97. Repligen has a one year low of $113.50 and a one year high of $211.13.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. During the same period in the previous year, the company posted $0.23 EPS. The firm’s revenue was up 9.7% on a year-over-year basis. Research analysts anticipate that Repligen will post 1.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Repligen

Several large investors have recently bought and sold shares of RGEN. Champlain Investment Partners LLC increased its stake in Repligen by 149.0% during the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after acquiring an additional 850,345 shares during the last quarter. Thrivent Financial for Lutherans boosted its holdings in shares of Repligen by 240.5% in the 2nd quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock worth $75,866,000 after purchasing an additional 425,061 shares during the period. DF Dent & Co. Inc. increased its position in shares of Repligen by 31.0% during the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after purchasing an additional 139,615 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Repligen by 39.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock valued at $54,149,000 after buying an additional 121,305 shares during the period. Finally, Two Sigma Advisers LP lifted its position in Repligen by 421.9% in the third quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company’s stock worth $18,796,000 after buying an additional 102,100 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.